Supplemental material
Leukemia & Lymphoma
Volume 62, 2021 - Issue 1
Original Articles
A multicenter comparative acute myeloid leukemia study: can we explain the differences in the outcomes in resource-constrained settings?
Douglas R. A. Silveiraa Service of Hematology, Transfusion and Cell Therapy and Laboratory of Medical Investigation in Pathogenesis and Directed Therapy in Onco-Immuno-Hematology (LIM-31) HCFMUSP, University of Sao Paulo Medical School, Sao Paulo, Brazil;b Department of Hematology, AC Camargo Cancer Center, Sao Paulo, BrazilCorrespondence[email protected]
https://orcid.org/0000-0001-5298-9592View further author information
https://orcid.org/0000-0001-5298-9592View further author information, Juan L. Coelho-Silvac Department of Medical Images, Hematology and Clinical Oncology, University of Sao Paulo at Ribeirao Preto Medical School (FMRP), Ribeirao Preto, Brazilhttps://orcid.org/0000-0001-8384-6551View further author information
https://orcid.org/0000-0001-8384-6551View further author information, , , Diego A. Pereira-Martinsc Department of Medical Images, Hematology and Clinical Oncology, University of Sao Paulo at Ribeirao Preto Medical School (FMRP), Ribeirao Preto, Brazilhttps://orcid.org/0000-0002-3302-4311View further author information
https://orcid.org/0000-0002-3302-4311View further author information, , , , , , , Eduardo M. Regoa Service of Hematology, Transfusion and Cell Therapy and Laboratory of Medical Investigation in Pathogenesis and Directed Therapy in Onco-Immuno-Hematology (LIM-31) HCFMUSP, University of Sao Paulo Medical School, Sao Paulo, Brazil;d Leukemia Unit, Cancer Institute of Sao Paulo (ICESP), University of Sao Paulo Medical School, Sao Paulo, Brazilhttps://orcid.org/0000-0003-1567-4086View further author information
https://orcid.org/0000-0003-1567-4086View further author information, Paresh Vyase Department of Haematology, Oxford University Hospitals NHS Foundation Trust, Oxford, UK;f MRC MHU, BRC Haematology Theme, Oxford Biomedical Research Center, Oxford Center for Hematology, WIMM, Radcliffe Department of Medicine, University of Oxford, Oxford, UK;g National Institute of Health Research Oxford, Biomedical Research Centre, Oxford, UKhttps://orcid.org/0000-0003-3931-0914View further author information
https://orcid.org/0000-0003-3931-0914View further author information, Fabiola Trainac Department of Medical Images, Hematology and Clinical Oncology, University of Sao Paulo at Ribeirao Preto Medical School (FMRP), Ribeirao Preto, Brazilhttps://orcid.org/0000-0003-4258-289XView further author information
https://orcid.org/0000-0003-4258-289XView further author information, Israel Bendita Service of Hematology, Transfusion and Cell Therapy and Laboratory of Medical Investigation in Pathogenesis and Directed Therapy in Onco-Immuno-Hematology (LIM-31) HCFMUSP, University of Sao Paulo Medical School, Sao Paulo, Brazilhttps://orcid.org/0000-0002-4751-1428View further author information
https://orcid.org/0000-0002-4751-1428View further author information, & Vanderson Rochaa Service of Hematology, Transfusion and Cell Therapy and Laboratory of Medical Investigation in Pathogenesis and Directed Therapy in Onco-Immuno-Hematology (LIM-31) HCFMUSP, University of Sao Paulo Medical School, Sao Paulo, Brazil;d Leukemia Unit, Cancer Institute of Sao Paulo (ICESP), University of Sao Paulo Medical School, Sao Paulo, Brazil;e Department of Haematology, Oxford University Hospitals NHS Foundation Trust, Oxford, UKhttps://orcid.org/0000-0003-0094-619XView further author information
https://orcid.org/0000-0003-0094-619XView further author information show all